Constellation Pharmaceuticals Announces Appointment to Board of Directors
20 Février 2019 - 1:00PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, today
announced that Scott Braunstein, M.D., has been appointed to its
Board of Directors.
Dr. Braunstein joins Constellation’s team with a track record of
growing emerging and established biopharmaceutical companies as an
investor and a pharmaceutical executive. He is currently
chairman of the board of directors of ArTara Therapeutics and a
member of the board of directors of several public and private
companies, including Esperion Therapeutics, Marinus
Pharmaceuticals, SiteOne Therapeutics, Trevena, and Ziopharm
Oncology. Previously he served as chief operating officer at
Pacira Pharmaceuticals. Prior to joining Pacira, Dr.
Braunstein was a healthcare portfolio manager at Everpoint Asset
Management. He spent 12 years with J.P. Morgan Asset
Management as a healthcare analyst and managing director in the
U.S. Equity team and as a portfolio manager in the Global
Healthcare team. He is currently an operating partner at
Aisling Capital. Dr. Braunstein began his career as a
physician and earned his medical degree from the Albert Einstein
College of Medicine.
“I’m thrilled to be joining the Constellation board at this time
of growth,” said Dr. Braunstein. “The Company has a strong
epigenetics platform and encouraging preliminary clinical data from
its lead programs in key areas of unmet need for myelofibrosis and
prostate cancer patients. I look forward to helping
Constellation in what we expect to be an exciting year of
data.”
“We welcome Scott to Constellation’s board,” said Jigar
Raythatha, President and Chief Executive Officer of Constellation
Pharmaceuticals. “He has a wealth of experience as an
executive and board member in the biopharmaceutical industry and as
a healthcare investor and practicing physician. This experience
will help our Company considerably as we advance toward our goal of
becoming a late-stage oncology development company.”
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of the EZH2
inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic
castration-resistant prostate cancer and other cancers as well as
the BET inhibitor CPI-0610 for the treatment of myelofibrosis. The
Company is also applying its broad research and development
capabilities to explore other novel targets that directly and
indirectly impact gene expression to fuel a sustainable pipeline of
innovative small-molecule product candidates.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, contained in
this press release, including statements regarding the Company’s
strategy, future operations, future financial position, prospects,
plans and objectives of management, are forward-looking statements.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in,
or implied by, such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks associated
with Constellation’s ability to: obtain and maintain necessary
approvals from the FDA and other regulatory authorities; continue
to advance its product candidates in clinical trials; replicate in
later clinical trials positive results found in preclinical studies
and early-stage clinical trials of CPI-1205, CPI-0610 and its other
product candidates; advance the development of its product
candidates under the timelines it anticipates, or at all, in
current and future clinical trials; obtain, maintain or protect
intellectual property rights related to its product candidates;
manage expenses; and raise the substantial additional capital
needed to achieve its business objectives. For a discussion of
other risks and uncertainties, any of which could cause the
Company’s actual results to differ from those contained in the
forward-looking statements, see the “Risk Factors” section, as well
as discussions of potential risks, uncertainties, and other
important factors, in the Company’s most recent filings with the
Securities and Exchange Commission. In addition, the forward-
looking statements included in this press release represent the
Company’s views as of the date hereof and should not be relied upon
as representing the Company’s views as of any date subsequent to
the date hereof. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. CPI-1205, CPI-0610, CPI-0209,
and other product candidates are investigational in nature and have
not yet been approved by the FDA or other regulatory
authorities.
Contact Ronald Aldridge Investor
RelationsConstellation Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024